非酒精性脂肪性肝炎治疗药物的进展  

Advances in therapeutic drugs for nonalcoholic steatohepatitis

作　　者：钱帅杰 谷劲岳 高锦航[2,3] 童欢[2,4] QIAN Shuaijie;GU Jinyue;GAO Jinhang;TONG Huan(West China Medical School,Sichuan University,Chengdu 610041,China;Lab of Gastroenterology and Hepatology,West China Hospital,Sichuan University,Chengdu 610041,China;Division of Peptides Related Human Disease,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Gastroenterology,West China Hospital,Sichuan University,Chengdu 610041,China)

机构地区：[1]四川大学华西临床医学院,成都610041 [2]四川大学华西医院消化疾病研究室,成都610041 [3]四川大学华西医院人类疾病相关多肽研究室,成都610041 [4]四川大学华西医院消化内科,成都610041

出　　处：《临床肝胆病杂志》2020年第12期2826-2830,共5页Journal of Clinical Hepatology

基　　金：国家自然科学基金青年科学项目(81700539);四川省科技计划项目(2020YFS0236)。

摘　　要：非酒精性脂肪性肝炎患病率逐年上升,对有效的治疗药物提出了迫切需求。近年来,相关药物不断涌现,种类繁多,包括:抗氧化应激药物、胰岛素增敏剂、PPAR激动剂、甲状腺受体激动剂、法尼酯X受体激动剂、ASK1抑制剂、全caspase激动剂等。精选关于非酒精性脂肪性肝炎治疗药物的临床研究进行回顾,总结各种药物的疗效及安全性,以期为临床实践提供参考意见。The incidence rate of nonalcoholic steatohepatitis is gradually increasing year by year,which calls for an urgent need for effective therapeutic drugs.In recent years,various drugs have been developed,including anti-oxidative stress drugs,insulin sensitizers,PPAR agonists,thyroid receptor agonists,farnesoid X receptor agonists,ASK1 inhibitors,and pan-caspase inhibitors.This article reviews the clinical studies on the therapeutic drugs for nonalcoholic steatohepatitis and summarizes the efficacy and safety of each drug,in order to provide a reference for clinical practice.

关 键 词：非酒精性脂肪性肝炎 药物疗法 随机对照试验(主题) 

分 类 号：R575.5[医药卫生—消化系统]